Halozyme Therapeutics (HALO)

Halozyme (HALO) Stock Price & Analysis


HALO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$29.85 - $59.40
Previous Close$39.95
Average Volume (3M)895.85K
Market Cap
Enterprise Value$6.32B
Total Cash (Recent Filing)$483.28M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)21.3
Feb 20, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.87
Shares Outstanding132,098,110
10 Day Avg. Volume859,760
30 Day Avg. Volume895,850
Standard Deviation0.13
Financial Highlights & Ratios
Price to Book (P/B)-8.06
Price to Sales (P/S)8.00
Price to Cash Flow (P/CF)10.00
P/FCF Ratio10.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.09
Enterprise Value/Gross Profit12.13
Enterprise Value/Ebitda15.54
Price Target Upside28.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9



Ownership Overview

12.28% Insiders
32.90% Mutual Funds
50.53% Other Institutional Investors
4.29% Public Companies and
Individual Investors


What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $29.85 and its highest was $59.40 in the past 12 months.
    What is Halozyme Therapeutics’s market cap?
    Currently, no data Available
    When is Halozyme Therapeutics’s upcoming earnings report date?
    Halozyme Therapeutics’s upcoming earnings report date is Feb 20, 2024 which is in 72 days.
      How were Halozyme Therapeutics’s earnings last quarter?
      Halozyme Therapeutics released its earnings results on Nov 06, 2023. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.706 by $0.044.
        Is Halozyme Therapeutics overvalued?
        According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Halozyme Therapeutics pay dividends?
          Halozyme Therapeutics does not currently pay dividends.
          What is Halozyme Therapeutics’s EPS estimate?
          Halozyme Therapeutics’s EPS estimate is $0.77.
            How many shares outstanding does Halozyme Therapeutics have?
            Halozyme Therapeutics has 132,098,110 shares outstanding.
              What happened to Halozyme Therapeutics’s price movement after its last earnings report?
              Halozyme Therapeutics reported an EPS of $0.75 in its last earnings report, beating expectations of $0.706. Following the earnings report the stock price went up 10.04%.
                Which hedge fund is a major shareholder of Halozyme Therapeutics?
                Among the largest hedge funds holding Halozyme Therapeutics’s share is Driehaus Capital Management LLC. It holds Halozyme Therapeutics’s shares valued at 20M.


                  Company Description

                  Halozyme Therapeutics

                  Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.


                  Top 5 ETFs holding HALO

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  FCF US Quality ETF
                  Vanguard Russell 3000 ETF
                  SPDR S&P 1500 Value Tilt ETF
                  Up to five ETFs with an Outperform Smart Score that hold HALO. The ETFs are listed according to market value of HALO within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Gilead Sciences

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis